Safety Pharmacology Society Webinar:

Drug Abuse Liability: Non-clinical and Clinical Perspectives

Moderator: Simon Authier, DVM, MBA, PhD, DSP
CiToxLAB
Agenda

Preclinical Abuse Liability Screening: Using The Troubles and Tribulations of Tramadol as a Model
David Gauvin, PhD, MPI

Clinical Drug Abuse Liability Testing
Lorraine Rusch, PhD, Vince and Associates Clinical Research
Joint NC3Rs and SPS Working Group coming soon!

Housing of non-rodents during the recording of cardiovascular data in safety pharmacology and toxicology studies

- Co-led by Anna Bottomley for NC3Rs, Jason Cordes (Pfizer) and Helen Prior (Independent) for SPS
- Survey into current practices to be distributed throughout SPS community w/c 18 May’15, for completion by end-June 2015
- Pilot working group (10 companies) have developed and trialled the survey
- Data to be released at workshop at SPS Annual Meeting in Prague on 1st October 2015
- If you do not receive the survey and wish to participate, please contact Anna.Bottomley@nc3rs.org.uk
SPS Survey on CNS Testing in Drug Development

Available on from the SPS website under News

144 participants to date!
Chance to Win a Ipad (2 prizes)
Deadline: May 30th
2015 Annual SPS Meeting
Registration now open

Abstract Deadline is June 15
2015 Annual SPS Meeting: Glance at the Program

Cardiovascular
  Cardiovascular Safety Assessment beyond ECG
  Translation QT
  CIPA on Your Mind?
  Case Studies in Diabetes and Pulmonary Arterial Hypertension

Central Nervous System
  Issue Resolution
  Sensory System Assessments in Safety Pharmacology
  Abuse liability

Novel In Vitro Models: Stem Cells to Human Tissues
NC3Rs Workshop (In Vitro)
Diplomate in Safety Pharmacology (DSP)

- Certification examination at the Annual Meeting
  - September 27, 2015
  - www.safetypharmacology.org/diplomate.asp
- 43 Diplomates in Safety Pharmacology
  - Industry
  - Academia
  - Regulatory Agency
Diplomate in Safety Pharmacology

- Registration now open!
- Industry Focused
  - 300 multiple choice questions
  - Peer reviewed process
- Major areas
  - Regulatory guidelines (10%)
  - Cardiovascular safety pharmacology (30%)
  - Neurological safety pharmacology (20%)
  - Respiratory safety pharmacology (15%)
Upcoming SPS Webinar

May 7, 2015 at 11AM Eastern time

Use of beat-to-beat ECG restitution for assessment of cardiac stress and arrhythmia vulnerability

Anthony Fossa, PhD
Fossa Consulting, LLC
Upcoming SPS Webinar

May 21, 2015 at 11AM Eastern time

Non-Clinical Safety Ophthalmology Studies

Margaret E. Collins, MS
Associate Director, Ocular Toxicology, Charles River

Brian Christian, PhD, DABT
Director, Nonclinical Safety Assessment, Covance

John Kapeghian, PhD, DABT
Senior Director Toxicology, CiToxLAB
Upcoming SPS Webinar

September 10, 2015 at 11AM Eastern time

Application of Model-based Quantitative Translation in Safety Pharmacology

Cheng Chang, PhD
Pfizer, Pharmacokinetics, Dynamics and Metabolism

Non-clinical drug abuse liability: A Regulatory Perspective

Jovita Randall-Thompson, PhD
Pharmacologist, Controlled Substance Staff, OCD/CDER/FDA
Upcoming SPS Webinar

October 29, 2015 at 11AM Eastern time

Non-clinical safety testing for central and distal axonopathies

**Joseph Arezzo**, PhD  
Professor of Neuroscience and Neurology  
Albert Einstein College of Medicine

CNS safety pharmacology: beyond core expectations

**Will Redfern**, BSc (Hons), PhD, FSB, FBPhS, DSP  
Drug Safety & Metabolism  
AstraZeneca UK
Questions and Discussions